Trial Data Anticipation: Social media discussions center on Invivyd's upcoming Phase 3 trial results for its infectious disease vaccine programs, with many highlighting the September readout as a key catalyst. Participants note the company's modest market capitalization and potential for substantial movement on positive outcomes amid a heating biotech environment. Recent sector gains tied to peers like Moderna have fueled comparisons and interest.
Stock Momentum Shift: Observers point to the recent price surge in Invivyd shares as evidence of pre-data positioning, with some describing it as a late-stage ramp ahead of clinical updates. The focus remains on trial endpoints for DECLARATION and LIBERTY studies and their implications for the vaccine market. Caution around insider activity appears alongside the optimism in these threads.
Sector Context: Broader conversations link Invivyd's prospects to evolving biotech trends, including acquisition activity and mRNA advancements that could create sympathetic momentum. Views emphasize the speculative nature of the position while underscoring the data's binary potential. Overall engagement reflects measured excitement without overstatement.
Note: This discussion summary was generated from an AI condensation of post data.
Invivyd Insider Trading Activity
Invivyd insiders have traded $IVVD stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $IVVD stock by insiders over the last 6 months:
- JILL ANDERSEN (Chief Legal Officer, Secretary) has made 0 purchases and 3 sales selling 102,901 shares for an estimated $107,907.
- WILLIAM E. DUKE (Chief Financial Officer) has made 0 purchases and 3 sales selling 61,744 shares for an estimated $64,747.
- JULIE GREEN (Chief Human Resources Officer) has made 0 purchases and 3 sales selling 61,744 shares for an estimated $64,747.
- TIMOTHY EDWARD LEE (Chief Commercial Officer) has made 0 purchases and 3 sales selling 61,744 shares for an estimated $64,747.
- ROBERT D. III ALLEN (Chief Scientific Officer) has made 0 purchases and 3 sales selling 57,114 shares for an estimated $59,892.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Invivyd Hedge Fund Activity
We have seen 69 institutional investors add shares of Invivyd stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 17,119,096 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $22,254,824
- BLACKROCK, INC. added 11,853,095 shares (+276.8%) to their portfolio in Q2 2026, for an estimated $10,340,640
- EVENTIDE ASSET MANAGEMENT, LLC removed 9,071,995 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,914,408
- BVF INC/IL added 8,640,000 shares (+44.3%) to their portfolio in Q2 2026, for an estimated $7,537,536
- POINT72 ASSET MANAGEMENT, L.P. added 7,498,130 shares (+17068.0%) to their portfolio in Q2 2026, for an estimated $6,541,368
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 3,630,351 shares (-43.0%) from their portfolio in Q2 2026, for an estimated $3,167,118
- BALYASNY ASSET MANAGEMENT L.P. removed 3,515,644 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,067,047
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Invivyd Price Targets
Multiple analysts have issued price targets for $IVVD recently. We have seen 2 analysts offer price targets for $IVVD in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Thomas Shrader from BTIG set a target price of $10.0 on 07/07/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $10.0 on 06/15/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
